Evicenter
MarkdownMedical informationP&T meetings
Vonaprument (ANX007)

Geographic atrophy secondary to age-related macular degeneration

Launch
Not announced
Last updated
167 sources

Executive summary

Conclusions

1 evidence topic · 11 sources

Summary
  • Development and regulatory status: vonaprument is investigational, and the sponsor states that it does not “have any products approved for sale”. The FDA has granted Fast Track designation and the EMA PRIME designation for geographic atrophy. The sham-controlled, double-masked phase 3 ARCHER II trial, ongoing in 659 participants, is the planned basis for both an EU filing (single study) and a U.S. filing (two pre-defined sub-studies). As of the sponsor's third-quarter 2026 results release, ARCHER II has reported no efficacy or safety results; the sponsor expects a Data Monitoring Committee assessment of the Month 15 primary endpoint in the fourth quarter of 2026, sub-study results in the first quarter of 2027 if that endpoint is met, and completion with the Month 24 analyses in the third quarter of 2027. The Form 10-Q states that “there is no assurance that either timepoint will show a statistically significant treatment effect”.
  • Clinical evidence and its limits: the efficacy evidence comes from one phase 2 trial, ARCHER, in 270 participants treated for 12 months. Its primary endpoint, the rate of change in GA lesion area at month 12, was not met (reductions of 6.2% with monthly dosing, p=0.526, and 1.3% with every-other-month dosing, p=0.896). The visual acuity finding is from a prespecified secondary analysis: BCVA loss of 15 or more letters occurred in 5 of 89 participants (5.6%) with monthly dosing and 19 of 89 (21.3%) with sham (p=0.0021), which the Form 10-K describes as “nominally statistically significant”; the registry reports 4 and 15 events under its definition of loss at 2 consecutive visits. After treatment stopped, the rate of BCVA ≥15-letter loss in the treated groups increased to parallel that of sham. No peer-reviewed publication reports ARCHER results, and a 2026 systematic review excluded them from its evidence synthesis for that reason.
  • Safety observed in ARCHER: serious adverse events occurred in 21 of 89 participants (23.60%) with monthly dosing, 16 of 92 (17.39%) with every-other-month dosing, and 16 of 89 (17.98%) with sham. Three serious events of endophthalmitis in treated participants were attributed to the injection procedure; intraocular inflammation occurred in 2 (2.2%) and 1 (1.1%) treated participants and none with sham, and one retinal vascular occlusion (1.1%) occurred with every-other-month dosing. No retinal vasculitis or ischemic optic neuropathy was reported, and choroidal neovascularization occurred in 4.5%, 4.3%, and 3.4% of participants (monthly, every other month, sham).
  • Position relative to the approved complement inhibitors: no trial has compared vonaprument with pegcetacoplan or avacincaptad pegol, and in 2025 the sponsor stated that it “no longer plans to conduct a second injection-controlled head-to-head Phase 3 trial”. Pegcetacoplan and avacincaptad pegol were approved on a reduction in the rate of GA expansion, with phase 3 functional data that “demonstrated no visual benefit”; ARCHER II instead uses BCVA ≥15-letter loss as its primary endpoint. The sponsor states that the two approved products “may pose competition for vonaprument, if approved”.
  • Unknowns for budget purposes: no price, wholesale acquisition cost, average sales price, or HCPCS code for vonaprument has been published, and no cost-effectiveness analysis, budget impact model, or health technology assessment of vonaprument was identified. The sponsor states that there is no assurance that a product “will be considered cost-effective by third-party payors”.